Reversal of gene expression changes in the colorectal normal-adenoma pathway by NS398 selective COX2 inhibitor

被引:59
作者
Galamb, O. [1 ,2 ]
Spisak, S. [1 ,2 ]
Sipos, F. [1 ]
Toth, K. [1 ]
Solymosi, N. [1 ]
Wichmann, B. [1 ]
Krenacs, T. [3 ]
Valcz, G. [1 ]
Tulassay, Z. [1 ,2 ]
Molnar, B. [1 ,2 ]
机构
[1] Semmelweis Univ, Dept Med 2, H-1088 Budapest, Hungary
[2] Hungarian Acad Sci, Mol Med Res Unit, Budapest, Hungary
[3] Semmelweis Univ, Dept Pathol & Expt Canc Res 1, H-1088 Budapest, Hungary
关键词
NS398; cyclooxygenase-2; colorectal cancer; adenoma; whole-genomic microarray; ENDOTHELIAL GROWTH-FACTOR; COLON-CANCER CELLS; CYCLOOXYGENASE-2; INHIBITOR; CONTROLLED-TRIAL; CELECOXIB; NS-398; PREVENTION; LIVER; INVASIVENESS; PROGRESSION;
D O I
10.1038/sj.bjc.6605515
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND AND AIMS: Treatment of colorectal adenomas with selective cyclooxygenase-2 inhibitors can contribute to the chemoprevention of colorectal cancer (CRC), but the molecular background of their effect is not fully understood. We analysed the gene expression modulatory effect of N-(2-cyclohexyloxy-4-nitrophenyl)-methanesulfonamide (NS398) on HT29 cells to be correlated with expression data gained from biopsy samples. METHODS: HT29 colon adenocarcinoma cells were treated with NS398, and global mRNA expression was analysed on HGU133Plus2.0 microarrays. Discriminatory transcripts between normal and adenoma and between adenoma and CRC biopsy samples were identified using HGU133Plus2.0 microarrays. The results were validated using RT-PCR and immunohistochemistry. RESULTS: Between normal and adenoma samples, 20 classifiers were identified, including overexpressed cadherin 3, KIAA1199, and downregulated peptide YY, glucagon, claudin 8. Seventeen of them changed in a reverse manner in HT29 cells under NS398 treatment, 14 (including upregulated claudin 8, peptide YY, and downregulated cadherin 3, KIAA1199) at a significance of P<0.05. Normal and CRC could be distinguished using 38 genes, the expression of 12 of them was changed in a reverse manner under NS398 treatment. CONCLUSION: NS398 has a reversal effect on the expression of several genes that altered in colorectal adenoma-carcinoma sequence. NS398 more efficiently inverted the expression changes seen in the normal-adenoma than in the normal-carcinoma transition. British Journal of Cancer (2010) 102, 765-773. doi:10.1038/sj.bjc.6605515 www.bjcancer.com Published online 19 January 2010 (C) 2010 Cancer Research UK
引用
收藏
页码:765 / 773
页数:9
相关论文
共 42 条
  • [1] Cyclooxygenase-2 inhibitors decrease vascular endothelial growth factor expression in colon cancer cells by enhanced degradation of Sp1 and Sp4 proteins
    Abdelrahim, M
    Safe, S
    [J]. MOLECULAR PHARMACOLOGY, 2005, 68 (02) : 317 - 329
  • [2] Aspirin and NS-398 inhibit hepatocyte growth factor-induced invasiveness of human hepatoma cells
    Abiru, S
    Nakao, K
    Ichikawa, T
    Migita, K
    Shigeno, M
    Sakamoto, M
    Ishikawa, H
    Hamasaki, K
    Nakata, K
    Eguchi, K
    [J]. HEPATOLOGY, 2002, 35 (05) : 1117 - 1124
  • [3] Cyclooxygenase-2 (PTGS2) inhibitors augment the rate of hexose transport in L6 myotubes in an insulin- and AMPKα-independent manner
    Alpert, E
    Gruzman, A
    Lardi-Studler, B
    Cohen, G
    Reich, R
    Sasson, S
    [J]. DIABETOLOGIA, 2006, 49 (03) : 562 - 570
  • [4] Celecoxib for the prevention of colorectal adenomatous polyps
    Arber, Nadir
    Eagle, Craig J.
    Spicak, Julius
    Racz, Istvan
    Dite, Petr
    Hajer, Jan
    Zavoral, Miroslav
    Lechuga, Maria J.
    Gerletti, Paola
    Tang, Jie
    Rosenstein, Rebecca B.
    Macdonald, Katie
    Bhadra, Pritha
    Fowler, Robert
    Wittes, Janet
    Zauber, Ann G.
    Solomon, Scott D.
    Levin, Bernard
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (09) : 885 - 895
  • [5] Inhibition of COX-2 with NS-398 decreases colon cancer cell motility through blocking epidermal growth factor receptor transactivation: possibilities for combination therapy
    Banu, N.
    Buda, A.
    Chell, S.
    Elder, D.
    Moorghen, M.
    Paraskeva, C.
    Qualtrough, D.
    Pignatelli, M.
    [J]. CELL PROLIFERATION, 2007, 40 (05) : 768 - 779
  • [6] A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas
    Baron, John A.
    Sandler, Robert S.
    Bresalier, Robert S.
    Quan, Hui
    Riddell, Robert
    Lanas, Angel
    Bolognese, James A.
    Oxenius, Bettina
    Horgan, Kevin
    Loftus, Susan
    Morton, Dion G.
    [J]. GASTROENTEROLOGY, 2006, 131 (06) : 1674 - 1682
  • [7] Celecoxib for the prevention of sporadic colorectal adenomas
    Bertagnolli, Monica M.
    Eagle, Craig J.
    Zauber, Ann G.
    Redston, Mark
    Solomon, Scott D.
    Kim, KyungMann
    Tang, Jie
    Rosenstein, Rebecca B.
    Wittes, Janet
    Corle, Donald
    Hess, Timothy M.
    Woloj, G. Mabel
    Boisserie, Frederic
    Anderson, William F.
    Viner, Jaye L.
    Bagheri, Donya
    Burn, John
    Chung, Daniel C.
    Dewar, Thomas
    Foley, T. Raymond
    Hoffman, Neville
    Macrae, Finlay
    Pruitt, Ronald E.
    Saltzman, John R.
    Salzberg, Bruce
    Sylwestrowicz, Thomas
    Gordon, Gary B.
    Hawk, Ernest T.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (09) : 873 - 884
  • [8] COX-2: A molecular target for colorectal cancer prevention
    Brown, JR
    DuBois, RN
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (12) : 2840 - 2855
  • [9] Non-steroidal anti-inflammatory drugs with activity against either cyclooxygenase 1 or cyclooxygenase 2 inhibit colorectal cancer in a DMH rodent model by inducing apoptosis and inhibiting cell proliferation
    Brown, WA
    Skinner, SA
    Malcontenti-Wilson, C
    Vogiagis, D
    O'Brien, PE
    [J]. GUT, 2001, 48 (05) : 660 - 666
  • [10] *CANC RES CAMP, 1999, CANC STAT LARG BOW